Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00178776
Other study ID # 5R01DA015453-02
Secondary ID R01DA015453-02UT
Status Completed
Phase Phase 1
First received September 13, 2005
Last updated January 10, 2017
Start date October 2003
Est. completion date June 2007

Study information

Verified date September 2014
Source National Institute on Drug Abuse (NIDA)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the feasibility and promise of a recently manualized group therapy based on the Transtheoretical Model for cocaine use disorders.


Description:

Cocaine use in the general population is a significant and costly problem. Novel and innovative interventions targeting cocaine abuse are needed. The Transtheoretical Model of behavior change (TTM) offers a comprehensive framework for understanding, measuring, and intervening in behavior change and provides a strong theoretical foundation upon which effective treatments for substance abuse can be developed. The proposed Stage 1 research will pilot test a novel and innovative behavioral group therapy for cocaine users based on the TTM. In Phase 1, investigators will modify the newly developed Group Treatment for Substance Abuse: A Stages-of-Change Therapy Manual (Velasquez, Maurer, Crouch & DiClemente, 2001) to specifically target cocaine abuse resulting in a twelve-session, group intervention and accompanying therapy manual based on the TTM stages and processes of change: six "early stage" sessions targeting the experiential processes of change, and six "later stage" sessions targeting the behavioral processes of change. Phase 2 will consist of a pilot trial to evaluate the TTM group therapy with cocaine abusing patients. A randomized, controlled, between groups design will be used in which cocaine abusers (N=80) are assigned to one of two group treatment conditions: TTM therapy or Education/Advice. Participants will be recruited from Houston and surrounding communities through the Substance Abuse Research Center at the University of Texas Health Science Center Mental Sciences Institute. We expect the delivery of the TTM therapy for cocaine users to be feasible and acceptable, and to produce significant patient improvement. Cocaine outcomes will be assessed via objective (urine and drug analysis) and self-report measures. This Stage I research will contribute important theoretical and empirical information concerning the promise of a new and innovative intervention for cocaine abusers, and will provide the basis for a larger efficacy trial.


Recruitment information / eligibility

Status Completed
Enrollment 138
Est. completion date June 2007
Est. primary completion date November 2006
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

Inclusion Criteria: Male and female adults (ages 18-65 years old), of any race, who meet DSM-IV criteria for cocaine abuse or dependence disorder will be recruited. In addition, eligible participants must be:

- (1) judged to be in generally good physical and psychiatric health except for possible acute drug related problems;

- (2) willing and able to participate in the 6-week, group outpatient treatment;

- (3) able to provide the name of at least one person who can generally locate their whereabouts; and

- (4) willing to be followed for 3 months after treatment ends.

Potential subjects with simple drug charges whose legal contacts are willing to forego data revelation will be included. Although cocaine dependence will be the primary drug for which patients are seeking treatment, we will not exclude participants who are abusing additional substances.

Exclusion Criteria:

Individuals will be ineligible for study participation based on the following criteria:

- (1) current diagnosis of an Axis I psychiatric disorder other than cocaine dependence;

- (2) current psychiatric symptoms requiring medication;

- (3) severe medical, cognitive and /or psychiatric impairment that precludes cooperation with study protocol;

- (4) substance withdrawal symptoms requiring medical attention;

- (5) currently receiving other psychosocial therapy for substance abuse with the exception of AA, NA or CA;

- (6) impending incarceration;

- (7) inability to read, write, speak English;

- (8) inability or unwillingness to participate in the 6-week, group outpatient treatment (e.g., halfway house or other aftercare program restrictions).

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
Transtheoretical Model Group Therapy

Education & Advice


Locations

Country Name City State
United States University of Texas Houston Mental Sciences Institute Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
National Institute on Drug Abuse (NIDA) The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

References & Publications (1)

Velasquez, M. M., Maurer, G. G., Crouch, C., & DiClemente, C. C. (2001). Group treatment for substance abuse: A stages-of-change therapy manual. New York: Guilford Press.

Outcome

Type Measure Description Time frame Safety issue
Primary Urinalysis indicating presence or absence of cocaine metabolites, used to calculate percent days abstinent, collected at intake, once weekly during the 6 week group treatment phase, at post-treatment, and 3 months.
Secondary Secondary Outcome Measures Related to Cocaine and other Drug Use:
Secondary 1) Timeline Follow-Back (self-reported use / percent days
Secondary abstinent)
Secondary 2) Cocaine Craving Worksheet (self report)
Secondary 3) Cocaine Negative Consequences Checklist (self report)
Secondary 4) Addiction Severity Index (ASI; Interviewer Administered)
Secondary 5) Blood Alcohol Breath (biological)
Secondary 6) Substance Use Report (self report)
Secondary Secondary Outcome Measures Related to Feasibility of the Group Therapy:
Secondary 1) Participation / Attendance / Retention
Secondary 2) MI Scale (Therapist Adherence)
Secondary 3) Treatment Satisfaction Questionnaire
Secondary 4) Group Therapy Alliance Scale
Secondary 5) Group Atmosphere Scale
Secondary 6) Therapist Treatment Evaluation
Secondary Secondary Outcome Measures Related to Psychiatric Symptoms:
Secondary 1) Beck Depression Inventory (BDI-II)
Secondary 2) Brief Symptom Inventory (BSI)
Secondary Secondary Outcomes Related to Functioning:
Secondary 1) HIV Knowledge Questionnaire
Secondary 2) Risk Behavior Assessment
Secondary 3) SF-12
See also
  Status Clinical Trial Phase
Completed NCT01639157 - Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine N/A
Completed NCT00759473 - D-Cycloserine Facilitation of Cocaine - Cue Extinction Phase 2
Completed NCT00780442 - D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals Phase 2
Recruiting NCT02680288 - Lorcaserin Intra Venous Cocaine Effects Phase 1/Phase 2
Completed NCT02909101 - Project IMPACT: Improving Memory Performance by Applying Cognitive Training N/A
Completed NCT01739192 - A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence Early Phase 1
Completed NCT01495195 - Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior Phase 2
Completed NCT02373124 - Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial Phase 1/Phase 2